Abstract
Amyloid beta (Aβ) binding alcohol dehydrogenase (ABAD) is a cellular cofactor for promoting (Aβ)-mediated mitochondrial and neuronal dysfunction, and cognitive decline in transgenic Alzheimer’s disease (AD) mouse models. Targeting mitochondrial ABAD may represent a novel therapeutic strategy against AD. Here, we report the biological activity of small molecule ABAD inhibitors. Using in vitro surface plasmon resonance (SPR) studies, we synthesized compounds with strong binding affinities for ABAD. Further, these ABAD inhibitors (ABAD-4a and 4b) reduced ABAD enzyme activity and administration of phosphonate derivatives of ABAD inhibitors antagonized calcium-mediated mitochondrial swelling. Importantly, these compounds also abolished Aβ-induced mitochondrial dysfunction as shown by increased cytochrome c oxidase activity and adenosine-5'-triphosphate levels, suggesting protective mitochondrial function effects of these synthesized compounds. Thus, these compounds are potential candidates for further pharmacologic development to target ABAD to improve mitochondrial function.
Keywords: ABAD inhibitors, adenosine-5'-triphosphate, amyloid beta, benzothiazole amino phosphonates, cytochrome c oxidase, mitochondrial dysfunction.
Current Alzheimer Research
Title:Identification of Human ABAD Inhibitors for Rescuing Aβ-Mediated Mitochondrial Dysfunction
Volume: 11 Issue: 2
Author(s): Koteswara R. Valaasani, Qinru Sun, Gang Hu, Jianping Li, Fang Du, Yaopeng Guo, Emily A. Carlson, Xueqi Gan and Shirley S. Yan
Affiliation:
Keywords: ABAD inhibitors, adenosine-5'-triphosphate, amyloid beta, benzothiazole amino phosphonates, cytochrome c oxidase, mitochondrial dysfunction.
Abstract: Amyloid beta (Aβ) binding alcohol dehydrogenase (ABAD) is a cellular cofactor for promoting (Aβ)-mediated mitochondrial and neuronal dysfunction, and cognitive decline in transgenic Alzheimer’s disease (AD) mouse models. Targeting mitochondrial ABAD may represent a novel therapeutic strategy against AD. Here, we report the biological activity of small molecule ABAD inhibitors. Using in vitro surface plasmon resonance (SPR) studies, we synthesized compounds with strong binding affinities for ABAD. Further, these ABAD inhibitors (ABAD-4a and 4b) reduced ABAD enzyme activity and administration of phosphonate derivatives of ABAD inhibitors antagonized calcium-mediated mitochondrial swelling. Importantly, these compounds also abolished Aβ-induced mitochondrial dysfunction as shown by increased cytochrome c oxidase activity and adenosine-5'-triphosphate levels, suggesting protective mitochondrial function effects of these synthesized compounds. Thus, these compounds are potential candidates for further pharmacologic development to target ABAD to improve mitochondrial function.
Export Options
About this article
Cite this article as:
Valaasani R. Koteswara, Sun Qinru, Hu Gang, Li Jianping, Du Fang, Guo Yaopeng, Carlson A. Emily, Gan Xueqi and Yan S. Shirley, Identification of Human ABAD Inhibitors for Rescuing Aβ-Mediated Mitochondrial Dysfunction, Current Alzheimer Research 2014; 11 (2) . https://dx.doi.org/10.2174/1567205011666140130150108
DOI https://dx.doi.org/10.2174/1567205011666140130150108 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Current Pharmaceutical Design Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research Chinese Herbs and Herbal Extracts for Neuroprotection of Dopaminergic Neurons and Potential Therapeutic Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Following Intracellular Cholesterol Transport by Linear and Non-Linear Optical Microscopy of Intrinsically Fluorescent Sterols
Current Pharmaceutical Biotechnology Cholesterol, Alzheimers Disease, Prion Disorders: A menage a trois?
Current Drug Targets Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Differential Regulation of Neurotoxin in HIV Clades: Role of Cocaine and Methamphetamine
Current HIV Research SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology Urinary Albumin to Creatinine Ratio as Potential Biomarker for Cerebral Microvascular Disease
Current Neurovascular Research Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Structural and Biochemical Investigation of Heptad Repeat Derived Peptides of Human SARS Corona Virus (hSARS-CoV) Spike Protein+
Protein & Peptide Letters Inhibitors and Modulators of β- and γ-Secretase
Current Topics in Medicinal Chemistry Effects of Opiates and HIV Proteins on Neurons: The Role of Ferritin Heavy Chain and a Potential for Synergism
Current HIV Research Improved Anti-inflammatory Activity and Potential Cytoprotective Properties of Tolfenamic Acid, Naproxen and Indomethacin Derivatives
Letters in Drug Design & Discovery VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research Persistent Hiccups as an Atypical Initial Presentation of COVID-19: A Case Report
Infectious Disorders - Drug Targets Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued)